- Home
- COF vs AMGN Comparison
COF vs AMGN Comparison
Compare COF & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COF
- AMGN
- Stock Information
- Founded
- COF 1988
- AMGN 1980
- Country
- COF United States
- AMGN United States
- Employees
- COF N/A
- AMGN N/A
- Industry
- COF Major Banks
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COF Finance
- AMGN Health Care
- Exchange
- COF Nasdaq
- AMGN Nasdaq
- Market Cap
- COF 136.1B
- AMGN 150.8B
- IPO Year
- COF 1994
- AMGN N/A
- Fundamental
- Price
- COF $222.98
- AMGN $277.64
- Analyst Decision
- COF Buy
- AMGN Hold
- Analyst Count
- COF 15
- AMGN 19
- Target Price
- COF $236.73
- AMGN $320.11
- AVG Volume (30 Days)
- COF 3.1M
- AMGN 1.9M
- Earning Date
- COF 10-23-2025
- AMGN 10-29-2025
- Dividend Yield
- COF 1.07%
- AMGN 3.37%
- EPS Growth
- COF N/A
- AMGN 110.88
- EPS
- COF N/A
- AMGN 12.23
- Revenue
- COF $23,773,000,000.00
- AMGN $34,917,000,000.00
- Revenue This Year
- COF $94.85
- AMGN $8.99
- Revenue Next Year
- COF $18.35
- AMGN $1.79
- P/E Ratio
- COF N/A
- AMGN $23.12
- Revenue Growth
- COF N/A
- AMGN 12.88
- 52 Week Low
- COF $132.61
- AMGN $253.30
- 52 Week High
- COF $232.45
- AMGN $339.17
- Technical
- Relative Strength Index (RSI)
- COF 54.66
- AMGN 38.19
- Support Level
- COF $220.64
- AMGN $275.16
- Resistance Level
- COF $226.28
- AMGN $285.29
- Average True Range (ATR)
- COF 4.14
- AMGN 4.72
- MACD
- COF -0.24
- AMGN -0.72
- Stochastic Oscillator
- COF 48.20
- AMGN 12.76
About COF Capital One Financial Corporation
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending still provides the majority of the bank's revenue.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.